AIZ vs IVZ

Assurant (AIZ) shows mixed financial health with a weak Piotroski F-Score of 4/9, indicating borderline stability, and lacks an Altman Z-Score, limiting distress risk assessment. The stock trades above its Graham Number of $204.04 at $233.39, suggesting a modest premium, but below the analyst target of $259.33. Strong earnings growth (YoY +102.7%) and consistent earnings beat rates (3 of last 4 quarters) support valuation, yet weak technicals (10/100) and negative insider activity raise caution. Profitability metrics like ROE (15.41%) and low debt/equity (0.38) are positives, but liquidity concerns are evident in a weak current ratio (0.41) and quick ratio (0.15).

Invesco Ltd. presents a stark contrast between deep value metrics and deteriorating fundamental health, highlighted by a weak Piotroski F-Score of 2/9. While the valuation is highly attractive with a Forward P/E of 8.84 and a PEG ratio of 0.38, the company struggles with a negative profit margin (-4.42%) and a current ratio below 1.0 (0.79), indicating liquidity pressures. Despite a massive 93% one-year price increase, the current technical trend is heavily bearish (10/100). The investment case rests on whether the low valuation provides enough margin of safety to offset the poor financial health scores.